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Abstract
Introduction: Manganese regulates many enzymes and is essential for normal development and body function.
Chronic manganese intoxication has an insidious and progressive course and usually starts with complaints of
headache, fatigue, sleep disturbances, irritability and emotional instability. Later, several organ systems may be
affected and, due to neurotoxicity, an atypical parkinsonian syndrome may emerge. With regard to neuropsychiatry,
an array of symptoms may develop up to 30 years after intoxication, of which gait and speech abnormalities,
cognitive and motor slowing, mood changes and hallucinations are the most common. Psychotic phenomena are
rarely reported.
Case presentation: We describe the case of a 49-year-old Caucasian man working as a welder who was referred
to our facility for evaluation of acute paranoid psychotic behavior. Our patient’s medical history made no mention
of any somatic complaints or psychiatric symptoms, and he had been involved in a professional career as a
metalworker. On magnetic resonance imaging scanning of his brain, a bilateral hyperdensity of the globus pallidus,
suggestive for manganese intoxication, was found. His manganese serum level was 52 to 97 nmol/L (range: 7 to 20
nmol/L). A diagnosis of organic psychotic disorder due to manganese overexposure was made. His psychotic
symptoms disappeared within two weeks of treatment with low-dose risperidone. At three months later, serum
manganese was decreased to slightly elevated levels and the magnetic resonance imaging T1 signal intensity was
reduced. No signs of Parkinsonism were found and a definite diagnosis of manganese-induced apathy syndrome
was made.
Conclusion: Although neuropsychiatric and neurological symptoms caused by (chronic) manganese exposure have
been reported frequently in the past, in the present day the disorder is rarely diagnosed. In this report we stress
that manganese intoxication can still occur, in our case in a confined-space welder, and may present clinically with
a paranoid psychotic state that necessitates a rapid diagnostic procedure in order to avoid the permanent
structural brain damage that may occur with chronic exposure.
Introduction
Manganese (Mn) is an essential trace element that regu-
lates and binds to many enzymes throughout the body.
In cases of overexposure via inhalation or ingestion, Mn
is highly toxic for several organ systems. Mn crosses the
blood-brain barrier by the same mechanism that iron
does. A peculiar neurological picture similar to Parkin-
son’s shaking palsy due to Mn intoxication was first
reported in 1837 [1]. In the first post-war decades of the
20th century, Mn intoxication was documented to occur
primarily in miners and welders, manifesting as
increased rates of, for example, digestive tract and lung
cancer, liver cirrhosis and heart disease. The most com-
mon somatic sequelae are hypertension and increased
heart rate due to blocking of calcium channels by Mn,
elevated cholesterol levels following reduced conversion
of cholesterol to bile acids and decreased fertility in
men as well as increased fetal abnormalities [2].
With respect to the central nervous system, Mn over-
exposure initially induces non-specific symptoms such
as headache, asthenia, irritability, fatigue, sleep distur-
bances and emotional instability. Later, a neurodegen-
erative syndrome with psychiatric symptoms, called
manganism, may develop that is characterized by
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speech, gait and balance problems on the one hand, and
obsessive-compulsive behaviors, hostility, mood changes,
psychotic experiences such as hallucinations and para-
noid ideation, and reduced cognitive flexibility on the
other hand [3-5].
In a previous report by Kim et al., an magnetic reso-
nance imaging (MRI) scan of an Mn-overexposed
patient showed a regional distribution of high signal
intensities in the globus pallidus (100%), midbrain
(80%), pituitary gland (43%) and putamen (16%) [6]. The
increased signal intensities in the nigrostriatal structures,
particularly the globus pallidus, are best demonstrated
on T1-weighted images and correlate positively with the
Mn concentration in the blood [7,8]. These findings cor-
respond with the neurological syndrome of atypical
parkinsonism that comprises, apart from general brady-
kinesia, rigidity and kinetic tremor, frequent dystonias
and a specific cock-walk gait with a tendency to fall for-
ward [9]. In contrast to the findings in patients with
Parkinson’s disease, positron emission tomography
(PET) studies in patients exposed to Mn in general
show no dopaminergic abnormalities [10]. Single-photon
emission computed tomography (SPECT) images of
dopamine transporter (DAT) also demonstrate an over-
all normal DAT uptake in the striatum [11]. More
recent findings in non-human primates suggest that
chronic Mn exposure induces a cellular stress response
leading to neurodegenerative changes in the frontal cor-
tex that coincide with subtle cognitive deficits [12-14].
In this report, we describe the case of a middle-aged
man referred to our out-patient clinic for psychiatric
evaluation because of an acute paranoid psychosis.
Case presentation
Our patient was a 49-year-old Caucasian man who’s
educational history showed he had completed primary
school only. He had been employed in a professional
capacity as a metalworker and welder for many years.
His somatic history mentioned only slight hypertension,
for which he was treated with 25 mg hydrochloro-
thiazide daily. He was referred for paranoid ideation,
thoughts of reference, sleep disturbances and bizarre
behaviors. A provisional diagnosis of acute paranoid
psychosis was made and our patient was subsequently
treated with 2 mg risperidone daily. Within two weeks
the psychotic symptoms gradually disappeared and the
dose of risperidone was lowered to 1 mg daily. Physical
and neurological assessments did not reveal any
abnormalities. Routine hematological and biochemical
tests, including hemoglobin, lipoprotein profile and fast-
ing glucose, were all within normal ranges. Borrelia and
lues serology results were negative. Use of medications
including over the counter preparations and illicit drugs
were excluded by systematic evaluation.
Since there was no personal psychiatric history or
family history of psychiatric diseases, a central nervous
system disorder was suspected. Subsequently, MRI scan-
ning of the brain was performed that demonstrated high
T1 signal intensity of the globus pallidus bilaterally
(Figure 1). Analysis of lumbar cerebrospinal fluid
showed no abnormalities. Based on the MRI findings,
the serum concentration of Mn was measured, which
appeared to be increased (52 to 97 nmol/L, reference
values: 7 to 20 nmol/L; Laboratories of Clinical Pharma-
cology, Radboud University Nijmegen, The Nether-
lands). A definite diagnosis of an organic psychotic
disorder due to Mn intoxication was made. As a conse-
quence, DAT-SPECT was performed that showed a nor-
mal uptake. Electrocardiography and X-ray of the thorax
as well as ultrasonography of the liver displayed no
abnormalities.
At three months after the initial referral, a follow-up
MRI of the brain again showed enhanced T1 signal
intensity in the same areas, but clearly to a lesser extent.
The serum Mn concentration had decreased to high
normal levels (31 to 36 nmol/L). On neuropsychiatric
evaluation, our patient presented with a flat affect and
mental dullness. There was a marked discrepancy
between his appearance and his stated age. A detailed
neurological examination disclosed, apart from a slug-
gish and indifferent attitude, no abnormalities, especially
no signs or symptoms indicative for a parkinsonian syn-
drome. With respect to psychopathology, using the ele-
ments of the Comprehensive Psychiatric Rating Scale
his thinking was slow and rigid and, apart from irritabil-
ity and impulsivity, no formal psychiatric disturbances
could be detected. His behavior was dominated by loss
of interest in daily activities and social withdrawal as
well as a lack of concern about his personal life and
intentions. A neuropsychological assessment demon-
strated a total IQ of 62 (Kaufman Adult Intelligence
Test), which is in agreement with the estimated pre-
morbid total IQ of 57 (National Adult Reading Test).
There was a slow speed of information processing and a
marked cognitive dysfunction with respect to attention,
memory (learning and retrieval) and executive function-
ing (flexibility and shifting).
At follow-up after six months, a further neuropsychia-
tric examination disclosed findings similar to those
obtained previously and treatment with risperidone was
discontinued. His wife reported that the changes in his
behavior, mood and interests had started insidiously
several years before the first psychotic symptoms. A
final diagnosis of apathy syndrome caused by chronic
overexposure to Mn was formulated. Subsequently, psy-
chosocial supportive therapy was given and our patient
will be re-examined twice yearly in order to monitor the
potential development of parkinsonian symptoms.
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Discussion
In our 49-year-old patient, a bilaterally increased signal
intensity in the globus pallidus on T1-weighted MRI
was found. It appeared to be caused by overexposure to
Mn as demonstrated by an elevated serum concentra-
tion of Mn. Therefore, a diagnosis of organic psychotic
disorder/apathy syndrome due to Mn intoxication was
made. This diagnosis was supported by the decrease of
serum levels of Mn and the reduction of bilateral globus
pallidus T1 signal intensities over a period of three
months. Extensive investigation of our patient’s environ-
ment revealed no potential sources for Mn exposure
other than occupational exposure.
For several decades it has been known that once the
neuropathology is clearly expressed at the clinical level,
Mn-caused damage to the central nervous system is
essentially irreversible and often evolutive [15]. Even-
tually, an atypical parkinsonian syndrome may emerge
that is characterized by gait and balance problems,
dysarthria and absence of rest tremor, and points at a
striatal-pallidal degeneration [3]. Whether recurrent
low-dose occupational exposure to Mn causes early
brain damage is still controversial [16].
Several studies have replicated the observation that the
nigrostriatal dopaminergic system is essentially intact in
manganism, which has become evident from normal
PET and DAT-SPECT findings. Thus, in cases of high
T1 signal in patients with a history of Mn exposure in
whom a normal PET/SPECT uptake is found, a diagno-
sis of Mn-induced parkinsonism is justified. If PET/
SPECT uptake is reduced and MRI shows no abnormal-
ities, a diagnosis of idiopathic Parkinson’s disease should
be made [11].
Although the results from a few older reports are
suggestive for some efficacy of treatment with L-3,4-
dihydroxyphenylalanine (L-dopa) or 5-hydroxytrypto-
phan in Mn-induced parkinsonism, no effect could be
demonstrated in the only placebo-controlled study [17].
This unresponsiveness to (L-dopa) is most likely related
to the difference in the pathophysiology between idio-
pathic and Mn-induced parkinsonism. It has been
repeatedly shown that Mn accumulation in the brain is
not associated with degeneration of nigrostriatal dopa-
minergic neurons [18].
With respect to possible ways to reduce Mn accumula-
tion in brain structures in order to prevent neurological
damage, chelating agents such as ethylenediaminetetra-
acetic acid (EDTA), have been reported to possibly gener-
ate some positive effects in the early stages of poisoning,
although sometimes only temporarily. In case of struc-
tural brain damage, however, chelating therapy cannot be
expected to bring about any improvement [19]. In the
latter condition, experimental treatment with para-amino-
salicylic acid (PAS), originally used for the treatment of
tuberculosis, has been applied with promising alleviation
of neurological symptoms [20].
With regard to the neuropsychiatric and psychological
effects of Mn overexposure, several domains of dysfunc-
tion can be delineated such as: emotional instability with
irritability, anxiety, impulsivity and hostility; psychotic
symptoms such as paranoid ideation and hallucinations;
compulsive behaviors; and cognitive dysfunctions, parti-
cularly slowing of information processing, reduced mental
flexibility and impaired attention and learning [5]. For
these areas of dysfunction, no specific psychopharmacolo-
gical strategies can be recommended other than the regu-
lar treatment modalities [4,9].
Conclusion
To the best of our knowledge, this is the first report of
Mn-induced paranoid psychosis due to confined-space
welding. The occurrence of subacute psychotic symptoms
in the absence of a psychiatric history may point towards
occupational diseases that in the modern world are now
rare. In the case of Mn exposure, treatment with EDTA
may be effective in the early stages. Later, however, when
the neurodegenerative parkinsonian syndrome has
become irreversible and sometimes progressive without
Figure 1 MRI scan of the brain of our 49-year-old patient exposed to Manganese. Bilateral high T1 signal intensity in the globus pallidus is
shown. Left: transversal view; right: coronal view.
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any further Mn exposure, no therapeutic options remain.
Therefore, prevention of Mn intoxication should be the
primary target.
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